Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5356778 | 1.00 | CES1 (0.35) | CES1 | |
| SCHEMBL581064 | 1.00 | CES1 (0.35) | CES1 | |
| SCHEMBL5651324 | 1.00 | CES1 (0.35) | CES1 | |
| SCHEMBL2285351 | 1.00 | CES1 (0.35) | CES1 | |
| SCHEMBL2805477 | 1.00 | CES1 (0.35) | CES1 | |
| SCHEMBL2305639 | 1.00 | CES1 (0.35) | CES1 | |
| SCHEMBL3857734 | 0.98 | CES1 (0.32) | CES1 | |
| SCHEMBL290664 | 0.92 | — | — | |
| SCHEMBL15792000 | 0.80 | CES1 (0.35) | CES1 | |
| SCHEMBL8000974 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028191-A1 | Azide Functionalized Poly(3-Hexylthiophene) and Method of Forming Same | BROOKHAVEN SCIENCE ASSOCIATES, LLC (US) | 2012-02-02 | — | — | US | claimed |
| EP-4737504-A2 | CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND FORMULATION AND APPLICATION THEREOF | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-4276090-B1 | CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND PREPARATION AND APPLICATION THEREOF | XIAMEN SINOPEG BIOTECH CO LTD (CN) | 2026-04-29 | — | — | EP | disclosed |
| US-12492202-B2 | Macrocyclic PAD4 inhibitors useful as immunosuppressant | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250346554-A1 | METHOD FOR PURIFYING COMPOSITION | JSR CORPORATION (JP) | 2025-11-13 | — | — | US | disclosed |
| EP-4450485-A1 | METHOD FOR PURIFYING COMPOSITION | JSR Corporation (JP) | 2024-10-23 | — | — | EP | disclosed |
| US-20240342088-A1 | CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND FORMULATION AND APPLICATION THEREOF | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2024-10-17 | — | — | US | disclosed |
| EP-4276090-A1 | CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND PREPARATION AND APPLICATION THEREOF | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2023-11-15 | — | — | EP | disclosed |
| US-20230203039-A1 | MACROCYCLIC PAD4 INHIBITORS USEFUL AS IMMUNOSUPPRESSANT | BRISTOL MYERS SQUIBB CO (US) | 2023-06-29 | — | — | US | disclosed |
| WO-2023112939-A1 | METHOD FOR PURIFYING COMPOSITION | JSR株式会社 | 2023-06-22 | — | — | WO | disclosed |
| US-20050288344-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. | 2005-12-29 | — | — | US | disclosed |
| WO-2005121150-A1 | POLYMERISABLE THIENO[3,2-b]THIOPHENES | MERCK PATENT GMBH (DE) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005086974-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005080369-A2 | REACTIVE MESOGENIC CHARGE TRANSPORT COMPOUNDS CONTAINING AT LEAST TWO THIOPHENE GROUPS | MERCK PATENT GMBH (DE) | 2005-09-01 | — | — | WO | disclosed |
| US-20050184274-A1 | Reactive mesogenic charge transport compounds | MERCK PATENT GMBH (DE) | 2005-08-25 | — | — | US | disclosed |
| EP-1545513-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050090640-A1 | Mono-, oligo-and polythieno[2,3-b]thiophenes | FLEXENABLE TECHNOLOGY LIMITED (GB) | 2005-04-28 | — | — | US | disclosed |
| WO-2005019184-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| EP-1510535-A1 | Mono-, Oligo- and Polythieno(2,3-b)thiophenes | MERCK PATENT GmbH (DE) | 2005-03-02 | — | — | EP | disclosed |
| WO-2004014316-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346554-A1 | METHOD FOR PURIFYING COMPOSITION | HSD17B7, AKR1C3, DEGS1 | CES1 79/4885 |
| US-20120028191-A1 | Azide Functionalized Poly(3-Hexylthiophene) and Method of Forming Same | NUDT1, NMT1, MPST | CES1 4849/4885 |
| US-20050288344-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | TTPA, HAVCR2, ZC3HAV1 | CES1 827/4885 |
| US-12492202-B2 | Macrocyclic PAD4 inhibitors useful as immunosuppressant | PADI4, PADI1, PADI2 | CES1 26/4885 |
| US-20240342088-A1 | CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND FORMULATION AND APPLICATION THEREOF | NPC1, SLC27A1, SLC7A1 | CES1 274/4885 |
| US-20230203039-A1 | MACROCYCLIC PAD4 INHIBITORS USEFUL AS IMMUNOSUPPRESSANT | PADI4, PADI1, PADI2 | CES1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.